Literature DB >> 3471518

The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B.

D Mastrangelo, R Mathison, H J Huggel, S Dion, P D'Orléans-Juste, N E Rhaleb, G Drapeau, P Rovero, D Regoli.   

Abstract

The rat isolated portal vein is a pharmacological preparation more sensitive to neurokinin B than to any other neurokinin or tachykinin. The preparation is more sensitive to C-terminal partial sequences of substance P (SP) particularly SP-(6-11) than to the whole undecapeptide. The order of potency of neurokinins is as follows: neurokinin B greater than neurokinin A greater than substance P. The preparation shows high sensitivity also to kassinin and eledoisin. Comparative tests performed with strips of the rat portal vein suspended in a microbath under continuous perfusion (system 1) or in ordinary baths for isolated smooth muscles (system 2) have given similar results and have shown that the myotropic effect of neurokinin B is not modified by a variety of antagonists of endogenous agents as well as by inhibitors of the arachidonic acid cascade. The present results suggest that neurokinin B contracts the rat portal vein by activating specific receptors, presumably located on the smooth muscle membrane, different from those of biologically active amines and peptides which are active stimulants of the vein. Neurokinin B is ten times more active than neurokinin A and at least 100 times more than substance P. Such an order of potency of agonists suggests the existence of a new neurokinin receptor type, particularly sensitive to neurokinin B.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3471518     DOI: 10.1016/0014-2999(87)90363-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist.

Authors:  C Garret; A Carruette; V Fardin; S Moussaoui; J F Peyronel; J C Blanchard; P M Laduron
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

2.  Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors.

Authors:  J W Constantine; W S Lebel; H A Woody
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

3.  Effect of SR 142801 on nitric oxide-dependent and independent responses to tachykinin NK3 receptor agonists in isolated guinea-pig colon.

Authors:  S Giuliani; C A Maggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-11       Impact factor: 3.000

4.  The mechanisms for tachykinin-induced contractions of the rabbit corpus cavernosum.

Authors:  Ryosuke Takahashi; Junji Nishimura; Katsuya Hirano; Seiji Naito; Hideo Kanaide
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Proceedings of the British Pharmacological Society. Leeds, 12th-14th July 1989. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

6.  Actions of tachykinins on the rabbit mesenteric artery: substance P and [Glp6,L-Pro9]SP6-11 are potent agonists for endothelial neurokinin-1 receptors.

Authors:  A Stewart-Lee; G Burnstock
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

7.  Pharmacological analysis of [3H]-senktide binding to NK3 tachykinin receptors in guinea-pig ileum longitudinal muscle-myenteric plexus and cerebral cortex membranes.

Authors:  S Guard; S P Watson; J E Maggio; H P Too; K J Watling
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

8.  Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms.

Authors:  Andrew D Grant; Roksana Akhtar; Norma P Gerard; Susan D Brain
Journal:  J Physiol       Date:  2002-09-15       Impact factor: 5.182

9.  FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity.

Authors:  H Morimoto; M Murai; Y Maeda; D Hagiwara; H Miyake; M Matsuo; T Fujii
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

10.  Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888.

Authors:  T Fujii; M Murai; H Morimoto; Y Maeda; M Yamaoka; D Hagiwara; H Miyake; N Ikari; M Matsuo
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.